Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Amlodipine and valsartan

(Exforge®)

Exforge®

Drug updated on 12/11/2024

Dosage FormTablet (oral; amlodipine/valsartan: 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg, 10 mg/320 mg)
Drug ClassCalcium channel blockers and angiotensin II receptor blockers
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled on monotherapy
  • Indicated for the treatment of hypertension as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • Azilsartan medoxomil (AZL-M) 80 mg ranked highest in antihypertensive efficacy, achieving a 93% effectiveness for systolic blood pressure (SBP) reduction and 90% for diastolic blood pressure (DBP) reduction, outperforming other drugs in BP control.
  • Among single-pill combination (SPC) therapies for uncontrolled essential hypertension, irbesartan/amlodipine showed the highest efficacy in SBP reduction (surface under the cumulative ranking curve (SUCRA): 92.2%), while amlodipine/losartan ranked highest for DBP reduction (SUCRA: 95.1%) and diastolic response rate (SUCRA: 84.5%), with telmisartan/amlodipine achieving the best BP control rate (SUCRA : 83.5%).
  • The combination of valsartan 320 mg with amlodipine 10 mg demonstrated optimal antihypertensive effects without significant adverse outcomes, while higher doses of valsartan combined with hydrochlorothiazide 25 mg did not yield further BP reductions.
  • Reported adverse effects for combinations involving valsartan included dizziness, headache, nasopharyngitis, asthenia, and urticaria, with no significant increase in permanent discontinuations due to adverse effects.
  • There is no population type or subgroup information available in the reviewed studies.